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PRACTICE | FIVE THINGS TO KNOW ABOUT ...
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Antidepressant discontinuation syndrome is common

Box 1: Prevention and management of
antidepressant discontinuation syndrome2,3,5

About 20% of patients develop antidepressant discontinuation syndrome
following an abrupt stoppage of or marked reduction in the dose of an
antidepressant taken continuously for one month.1 Symptoms are usually
mild and may occur following treatment with any type of antidepressant.
Symptoms occur within two to four days after drug cessation and usually
last one to two weeks (occasionally may persist up to one year). If the same
or a similar drug is started, the symptoms will resolve within one to
three days. Sociodemographic and clinical factors associated with
increased vulnerability have not been identified.2 Among the serotonin
reuptake inhibitors, paroxetine is associated with the highest incidence of
the syndrome and fluoxetine with the lowest. Because of venlafazine’s
short half-life, the syndrome may occur more frequently following cessation and symptoms may be more severe.1

•
•
•
•
•

Symptoms are vague and variable
Failure to recognize antidepressant discontinuation syndrome may result in
medical or psychiatric misdiagnosis. The mnemonic FINISH summarizes the
symptoms of antidepressant discontinuation syndrome: Flu-like symptoms
(lethargy, fatigue, headache, achiness, sweating), Insomnia (with vivid
dreams or nightmares), Nausea (sometimes vomiting), Imbalance (dizziness,
vertigo, light-headedness), Sensory disturbances (“burning,” “tingling,” “electric-like” or “shock-like” sensations) and Hyperarousal (anxiety, irritability,
agitation, aggression, mania, jerkiness).3

The syndrome needs to be distinguished from relapse
Cessation of antidepressant therapy may increase the risk of relapse of
depression or anxiety. Unlike the symptoms of antidepressant discontinuation syndrome, symptoms of relapse usually take more than a few days to
appear and to disappear following reintroduction of the antidepressant.4

Patient education may reduce risk
Physicians should be vigilant at times when patients may consider stopping an
antidepressant (e.g., during pregnancy). Because not all formulations of the
same drug are bioequivalent, there may be an unintended reduction in drug
concentration if an antidepressant is switched to another formulation. To minimize risk of the syndrome, patients should be encouraged to consult their
physician before stopping an antidepressant. Prescribing an antidepressant
with a longer half-life or tapering the medication over six to eight weeks may
reduce the risk.4

Treatment of the syndrome needs to be individualized
Management of antidepressant discontinuation syndrome needs to be done
on an individual basis because of a lack of specific treatment data (Box 1).2,3,5
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Tapering may not be necessary for patients
taking an antidepressant for less than
four weeks or those who are taking fluoxetine.
Faster tapering may be possible in cases where
doses are low.
Antidepressants with short half-lives need to be
tapered gradually; however, gradual tapering may
not prevent the syndrome in all cases.
Patients should be reassured that symptoms are
reversible, not life-threatening and usually selflimiting.
Switching to fluoxetine when considering
stopping another antidepressant may be helpful
in some cases.
If symptoms are severe, the drug should be
reintroduced and a slower taper started.
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